Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eliglustat - Sanofi

Drug Profile

Eliglustat - Sanofi

Alternative Names: Cerdelga; Eliglustat; Eliglustat tartrate; Genz-112638; GZ 385660

Latest Information Update: 03 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Michigan
  • Developer Sanofi Genzyme
  • Class 2 ring heterocyclic compounds; Amides; Pyrrolidines; Small molecules
  • Mechanism of Action Glucosylceramide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gaucher's disease type I
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gaucher's disease type I
  • Phase III Gaucher's disease type III

Most Recent Events

  • 13 Jun 2019 Efficacy data from a phase II and the phase III ENGAGE trial in Gaucher's disease type I presented at the 24th Congress of the European Haematology Association (EHA-2019)
  • 31 Jul 2018 Sanofi announces intention to submit regulatory application for Gaucher's disease type I (In children) in 2022 in EU
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top